Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...

Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

The FDA has granted a priority review to dordaviprone for treating patients with recurrent H3K27M-mutant diffuse glioma, a ...

Equities research analysts at Wedbush boosted their FY2028 earnings per share estimates for shares of Chimerix in a research note issued on Tuesday, February 18th. Wedbush analyst D. Nierengarten now ...

Chimerix (NASDAQ:CMRX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They ...

Shares of Chimerix (NASDAQ: NASDAQ: CMRX) climbed 12.5% as the company announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for dordaviprone, a potential ...

Investigational drug SPN-820, which activates the mTORC1 pathway, failed to significantly reduce depressive symptoms compared ...

TUESDAY, Feb. 25, 2025 (HealthDay News) -- More emergency room doctors in California are prescribing the anti-addiction ...

These new data further validate TP-317’s unique mechanism of action and its potential as an oral, first-in-class therapy for IBD,” said Gary Mathias, CEO of Thetis Pharmaceuticals. “The preclinical ...